[Sizofiran and recombinant interferon gamma stimulate peritoneal macrophages obtained from patients with gynecologic malignancies--increased secretion of tumor necrosis factor, IL-1 and interferon-gamma].

In: Gan to kagaku ryoho. Cancer & chemotherapy · 1990 · vol. 17(7) , pp. 1365–9 · PMID:2142400 · W2404761721
article OA: closed CC0
View on OpenAlex View on PubMed
⚙ AI-generated summary by qwen3.7-flash, 2026-08-25 ⓘ

Treatment of peritoneal macrophages from patients with cervical or ovarian cancer with sizofiran or recombinant interferon gamma significantly increased the secretion of tumor necrosis factor, IL-1, and interferon-gamma without altering prostaglandin E2 levels.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

TNF, IL-1, IFN-gamma and PGE2 secretion of peritoneal macrophage obtained by peritoneal washing at the first day after laparotomy from 19 patients with cervical cancer and 19 with ovarian cancer, who were treated with sizofiran (SPG) intramuscularly before laparotomy or with recombinant interferon gamma (rIFN) intraperitoneally at the day of laparotomy, were studied. Treatment with SPG and rIFN significantly increased the number and secretion of TNF, IL-1 and IFN-gamma (p less than 0.05) but not that of PGE2. A high correlation between secretion of TNF and IFN-gamma (r = 0.99, p less than 0.01) was observed. These data suggest that potent tumoricidal activity of peritoneal macrophage obtained from the patients with gynecological malignancies could be expected by the treatment with SPG and rIFN due to the increased secretion of TNF, IFN-gamma and IL-1 and inhibition of increased secretion of PGE2.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK